Progress, Potential, and Possibilities

Send us Fan MailWhat if a simple blood test could detect Alzheimer's years—maybe even decades—before symptoms ever appear?Mike Banville is the Chief Executive Officer of ALZpath ( https://alzpath.bio/ ), a company at the forefront of transforming how Alzheimer's disease is detected and monitored through cutting-edge blood-based diagnostics.Mike is a seasoned global executive with a track record of scaling businesses, driving operational transformation, and executing strategic growth through both organic expansion and acquisitions. Prior to ALZpath, he served as CEO of SSB - doubling revenue and shifting the business to a predominantly recurring revenue model.Earlier in his career, Mike spent over two decades at IHS Markit, where he held multiple senior leadership roles across strategy, sales, marketing, and global operations. There, he helped scale the Telecommunications, Media, and Technology division through acquisitions and product integration, while also leading global offshoring strategy and climate-focused market development initiatives.Mike has also led and turned around companies in digital health and athlete development, bringing a consistent focus on data, analytics, and scalable platforms.Now at ALZpath, Mike is applying that same operational and strategic expertise to one of the most urgent challenges in medicine - enabling earlier, more accessible detection of Alzheimer's disease through innovative biomarker technologies, like pTau217, helping accelerate research, improve clinical care, and ultimately impact millions of patients worldwide.#Alzheimers #AlzheimersDisease #Dementia #BrainHealth #Longevity #Biotech #HealthcareInnovation #Diagnostics #BloodTest #EarlyDetection #Neuroscience #Neurodegeneration #PrecisionMedicine #FutureOfMedicine #MedTech #Biomarkers #TauProtein #pTau217 #StartupCEO #BiotechCEO #HealthcarePodcast #MedicalBreakthrough #AgingResearch #CognitiveHealth #LifeSciencesSupport the show

Send us Fan MailThere's a revolution happening in pet health right now - where a simple stool sample can reveal disease risk, immune health, and even how long your dog might live.Dr. Bushra Schuitemaker, Ph.D. is a microbiologist, zoologist, and science leader working at the cutting edge of microbiome research, animal health, and nutrition. Dr. Schuitemaker serves as Head of Science and Research at BIOME9 ( https://biome9.com/ ), a leading platform for canine gut microbiome analysis, and Head of Microbiology at Pooch & Mutt ( https://www.poochandmutt.co.uk/ ), where she helps translate microbiome science into real-world products and interventions for pet health.Dr. Schuitemaker's work sits at the intersection of microbial ecology, bioinformatics, and machine learning, where she develops tools to decode the gut microbiome and turn complex data into actionable insights for veterinarians, pet owners, and the pet food industry. Her expertise spans metagenomics, metabolomics, and multi-omics integration, with a focus on identifying biomarkers that can drive precision health approaches in animals.Dr. Schuitemaker completed her Ph.D. in Zoology at the University of East Anglia, where she pioneered microbiome-based biomarkers of poultry gut health, and has also contributed to human health research, including microbiome and metabolomics studies in childhood obesity.A passionate advocate for “One Medicine” - the idea that human and animal health are deeply interconnected - Dr. Schuitemaker is also an active science communicator, collaborating across academia, industry, and policy to make microbiome science more impactful, inclusive, and accessible.#Microbiome #DogHealth #GutHealth #CanineMicrobiome #PetHealth #DogLongevity #VeterinaryScience #OneMedicine #OneHealth #PrecisionNutrition #Bioinformatics #MachineLearning #AnimalHealth #PetCare #DogsOfYouTube #DogWellness #HealthScience #FutureOfMedicine #LongevityScience #Metagenomics #Biome9 #PoochAndMutt #SciencePodcast #Biotech #AgingResearchSupport the show

Send us Fan MailWhat if most dogs aren't dying of old age - but from losing their ability to move?Dr. Laurie McCauley, DVM, DACVSMR, CCRT, CVA, CVC is a pioneer in veterinary rehabilitation and one of the most influential figures in canine sports medicine. With over two decades at the forefront of the field, she founded the first dedicated veterinary rehabilitation clinic in the United States and designed the world's first underwater treadmill specifically for dogs - innovations that helped transform how veterinarians approach mobility, recovery, and performance in animals.A board-certified specialist in Canine Sports Medicine and Rehabilitation, Dr. McCauley has trained thousands of veterinarians, physical therapists, and rehabilitation professionals around the world, and her work has played a central role in shaping modern standards of care.Dr. McCauley is the founder and instructional director of Optimum Pet Vitality ( https://optimumpetvitality.com/ ), an education platform focused on delivering evidence-based, practical training to veterinary professionals and pet owners alike, covering areas such as therapeutic exercise, laser therapy, and fascia-based treatments.In addition, Dr. McCauley is the owner of Red Tail Rehab, where she provides personalized, in-home rehabilitation care, helping animals improve mobility, reduce pain, and enhance quality of life.Dr. McCauley's career has been defined by a singular mission: to help animals move better, feel better, and ultimately live longer, healthier lives.#DogLongevity #PetHealth #CanineRehab #DogAging #VeterinaryMedicine #PetWellness #HealthyPets #DogHealth #LongevityScience #AnimalHealth #PetCareTips #SeniorDogs #CanineHealth #MobilityMatters #PetLongevity #VeterinaryRehabilitation #DogFitness #AgingResearch #BiohackingPets #HealthspanSupport the show

Send us Fan MailWhat if paralysis wasn't permanent—but just a biological system we haven't figured out how to reboot?Dr. Lior Shaltiel, Ph.D. is Chief Executive Officer of NurExone Biologic ( https://nurexone.com/ ), a biotech company pioneering a novel exosome-based platform aimed at repairing the central nervous system.Dr. Shaltiel brings a rare combination of deep scientific training and cross-border biotech leadership. He earned his Ph.D. in molecular pharmacology from Ludwig Maximilian University of Munich, where his research focused on ion channels and retinal biology - early work that connects directly to today's frontier in neuroregeneration.Before stepping into the CEO role, Dr. Shaltiel led R&D programs in advanced drug delivery systems, including liposome-based therapeutics, and worked in global biotech investment and partnerships. He's also the founder of the BioMed MBA program at Hebrew University of Jerusalem, helping train the next generation of biotech leaders.At NurExone, Dr. Shaltiel is advancing the company's ExoTherapy platform - leveraging extracellular vesicles to deliver targeted genetic payloads. Their lead program, ExoPTEN, is an intranasal exosome therapy designed to silence the PTEN gene and promote neuronal regeneration after spinal cord injury - an area where, to date, there are no approved treatments that restore lost function.#biotech #neuroscience #spinalcordinjury #regenerativemedicine #exosomes #stemcells #futureofmedicine #geneediting #biotechinnovation #medicalbreakthrough #neuroregeneration #sciencepodcast #healthtech #longevity #drugdiscovery #PTEN #RNAi #nextgenmedicine #biophysics #medtechSupport the show

Send us Fan MailWhat if the biggest barrier in healthcare today isn't science - but stigma?Eric Foster is Chief Commercial Officer at Ardelyx ( https://ardelyx.com/ ), a biopharmaceutical company where he leads global commercialization strategy for innovative therapies addressing high-burden gastrointestinal and cardiorenal diseases. A seasoned biotech executive with over two decades of experience, Eric has built and scaled high-performing commercial organizations across some of the industry's most complex and competitive markets.Prior to Ardelyx, Eric held senior leadership roles at Amgen and Horizon Therapeutics, where he led rare disease and specialty business units, overseeing product launches, market access, and global growth strategy. Earlier in his career, he spent over a decade at GSK and began in commercial roles at Johnson & Johnson.Eric is known for his expertise in rare disease commercialization, payer strategy, and building first-in-class market entry plans, with a strong focus on connecting patients to therapies and reducing barriers to care. He holds an MBA in Healthcare from Auburn University and a BA in Economics from the University of Georgia.#IBSC #GutHealth #WomensHealth #HealthcareInnovation #Biotech #PharmaMarketing #LPGA #WomensSports #DigitalHealth #PatientAwareness #ChronicIllness #HealthEducation #MedicalInnovation #HealthcareMarketing #BehaviorChange #HealthStigma #ChronicDisease #Biopharma #HealthPodcast #FutureOfHealthcareSupport the show

Send us Fan MailWhat if we could restore vision, communicate directly with the brain, and even extend human life—not with machines alone, but with living, engineered biology?Dr. Alan Mardinly, Ph.D. is the Chief Scientific Officer and Co-Founder of Science Corp. ( https://science.xyz/ ), a neurotechnology company developing next-generation brain interfaces and biohybrid neural implants aimed at restoring human function.Dr. Mardinly leads the company's biohybrid program, focused on combining genetically engineered cells with advanced optical hardware to create optogenetic therapies for vision restoration and new types of brain-machine interfaces.Dr. Mardinly has spent more than 15 years working at the intersection of neuroscience, genetics, and neural engineering. Dr. Mardinly earned his PhD in Neurobiology from Harvard University, where his research explored how experience and activity-dependent gene programs shape synaptic plasticity in inhibitory neurons—work that helped illuminate how neural circuits maintain stability while adapting to learning and sensory experience.Following Harvard, Dr. Mardinly conducted postdoctoral research at UC Berkeley, where he helped pioneer holographic optogenetics, a technology capable of stimulating specific neurons with extraordinary spatial and temporal precision.Dr. Mardinly later joined Neuralink, where he served as Director of Biology, leading teams focused on advancing brain-machine interface technologies. In 2021, Dr. Mardinly co-founded Science Corp., where he now works to translate cutting-edge neuroscience into therapeutic systems designed to restore vision and build the next generation of neural interfaces.#Neurotechnology  #BrainComputerInterface #Optogenetics #VisionRestoration #Biohybrid #ScienceCorp #Neuralink #FutureOfMedicine #BrainImplants #ArtificialVision #Neuroscience #Biotech #Longevity #LifeSupport #SyntheticBiology #HumanAugmentation #NextGenMedicine #DeepTech #Innovation #FutureOfHealthcareSupport the show

Send us Fan MailThere are over 9,000 rare diseases affecting 300 million people—and yet 90% of them have no approved treatment. Why?Craig Martin is the Founder and CEO of Orphan Therapeutics Accelerator ( https://www.orphantxl.com/ ), a pioneering nonprofit launched in 2024 to advance shelved therapies for ultra-rare diseases—bringing overlooked science back to life and guiding it through approval and into patients' hands through innovative development and commercialization pathways.With more than two decades at the intersection of biotech, digital health, and healthcare strategy, Craig has built a career around unlocking value in overlooked opportunities and tackling some of medicine's toughest challenges. He previously founded Rithm Health, where he has advised emerging biotech and health technology companies on strategy, growth, and stakeholder engagement.Craig also served as CEO of Global Genes, one of the world's leading rare disease patient advocacy organizations, where he reversed declining revenues, launched major new initiatives, and led a successful merger with RARE-X—expanding the organization's impact across the rare disease ecosystem.Earlier in his career, Craig spent over a decade leading Ogilvy | Feinstein Kean Healthcare, and held leadership roles at Ogilvy Consulting and Ruder Finn, advising global pharma, biotech, and health innovators.A graduate of Duke University, Craig brings a unique blend of strategic insight, policy awareness, and deep commitment to patients—focused on transforming how therapies for ultra-rare diseases are developed, financed, and delivered.#RareDisease #UltraRareDisease #Biotech #HealthcareInnovation #DrugDevelopment #GeneTherapy #OrphanDrugs #Pharma #MedicalInnovation #FutureOfMedicine #HealthTech #LifeSciences #BiotechInnovation #DrugDiscovery #PatientAccess #Healthcare #Medicine #Science #Innovation #NonprofitBiotech #RareDiseaseAwareness #GlobalHealthSupport the show

Send us Fan MailInside a fusion reactor, you're not just creating a star—you're building a machine that has to survive one. Temperatures hotter than the sun, relentless neutron bombardment… and materials that slowly destroy themselves from the inside out.Daniel Clark is a nuclear engineer and fusion energy expert working at the forefront of turning fusion from a scientific pursuit into a practical energy solution.Daniel is currently Director of Nuclear and Fuel Cycle Engineering at Type One Energy Group ( https://typeoneenergy.com/ ), where he leads critical efforts in breeder blanket and first wall design, as well as the tritium fuel cycle - core systems that will ultimately determine whether fusion reactors can operate sustainably at scale.Prior to joining the private sector, Daniel spent nearly eight years at the U.S. Department of Energy Office of Science, where he managed the Fusion Materials Research Portfolio. During that time, he helped launch major national initiatives, including the Material Plasma Exposure eXperiment at Oak Ridge National Laboratory, the INFUSE public-private partnership program, and the Fusion Prototypic Neutron Source.With degrees in nuclear engineering from Texas A&M University and University of Tennessee, Knoxville, Daniel brings a rare combination of deep technical expertise, federal policy insight, and commercialization experience—making him one of the key voices shaping the future of fusion energy.#FusionEnergy #NuclearFusion #CleanEnergy #FutureOfEnergy #EnergyInnovation #DeepTech #ClimateTech #Physics #NuclearEngineering #MaterialsScience #EnergyTransition #Tritium #SciencePodcast #TechPodcast #HardTech #Engineering #Innovation #FusionPower #StartupEnergy #BigScience #NextGenEnergy #AdvancedMaterials #EnergyFuture #BreakthroughScience #ClimateSolutionsSupport the show

Send us Fan MailWhat if the reason we haven't explored deep space isn't because we can't… but because our engines are fundamentally too slow?Richard Dinan is Founder and CEO of Pulsar Fusion ( https://pulsarfusion.com/ ) and one of the few entrepreneurs in the world not trying to bring fusion power to Earth… but to space.While most fusion startups are focused on powering cities, Richard is building engines designed to power spacecraft—fusion propulsion systems that could dramatically cut travel times to Mars, unlock missions to Saturn's moon Titan, and fundamentally reshape how we explore the solar system.Pulsar's flagship efforts—including its Dual Direct Fusion Drive and the Sunbird program—aim to combine high-thrust propulsion with onboard power generation, a combination that could enable entirely new classes of deep-space missions. The company is now working with the United Kingdom Atomic Energy Authority on advanced neutron shielding and activation modeling—critical challenges for making fusion viable and safe in space.Backed by the UK Space Agency and collaborating with the European Space Agency, Pulsar is positioning itself at the center of a new space race—one where the bottleneck isn't getting off Earth… but moving once you're already out there.On this episode we talk about why space might be the first place fusion actually works, what it takes to build engines that can survive neutron bombardment, and whether radically faster travel could open up the outer solar system within our lifetime.#fusionenergy #spacetechnology #spaceexploration #marsmission #deepspace #futureofspace #nuclearfusion #fusionpropulsion #spacex #nasa #spaceinnovation #aerospace #futuretech #pulsarfusion #richarddinan #sciencepodcast #techpodcast #engineering #physics #spacefuture #interplanetary #spaceindustry #nextgentech #hardtech #innovation #elonmusk #spaceeconomy #ukspace #europespace #austintechSupport the show

Send us Fan MailImagine treating back pain not with surgery, not with opioids—but by using your own stem cells to repair the damage at its source.Lance Alstodt is President, CEO, and Chairman of BioRestorative Therapies, Inc. ( https://biorestorative.com/ ), a publicly traded regenerative medicine company focused on developing stem cell-based therapies to treat highly prevalent conditions, including chronic lower back pain and metabolic disorders.With more than 25 years of experience across healthcare investment banking, medical technology, and company building, Lance brings a unique perspective at the intersection of science and capital markets. Prior to joining BioRestorative, he was the founder and CEO of MedVest Consulting, advising healthcare companies on growth strategy, M&A, and capital formation.Earlier in his career, Lance held senior leadership roles at firms including Leerink Partners, Oppenheimer & Co., Bank of America Merrill Lynch, and JPMorgan Chase & Co., where he specialized in healthcare and medical technology transactions.At BioRestorative, Lance is leading the development of innovative cell therapies such as BRTX-100, an autologous mesenchymal stem cell therapy currently in Phase 2 trials for chronic lumbar disc disease, aiming to offer a non-opioid, non-surgical solution to one of the most widespread causes of disability worldwide.#StemCells #RegenerativeMedicine #BackPainRelief #Biotech #HealthcareInnovation #MedicalBreakthrough #ChronicPain #BioTech #FutureOfMedicine #StemCellTherapy #DegenerativeDiscDisease #PainManagement #HealthTech #BiotechStocks #Longevity #MedicalInnovation #CellTherapy #NonSurgicalTreatment #OpioidCrisis #SciencePodcast #HealthcareRevolutionSupport the show

Send us Fan MailWhat if we could build a fusion reactor that runs continuously—without the instability issues that have plagued the field for years?Brian Berzin is the Co-Founder and CEO of Thea Energy ( https://thea.energy/ ), a next-generation fusion company focused on advancing stellarator technology—one of the most promising but historically underexplored approaches to magnetic confinement fusion.Brian brings a unique combination of deep technical and financial expertise, with a background spanning electrical engineering, venture capital, private equity, and investment banking. Prior to founding Thea Energy, Brian served as Vice President of Strategy at General Fusion, where he helped shape commercialization strategy and led engagement with global capital markets during a pivotal period for privately funded fusion.At Thea Energy, Brian is leading efforts to “end the sun's monopoly on fusion energy” by leveraging breakthroughs in high-temperature superconducting materials and advanced computational design to build more stable and scalable fusion systems. In 2023, the company was selected as one of a small group of awardees in the U.S. Department of Energy's milestone-based fusion development program.Brian holds dual degrees in Electrical Engineering and Finance from Lehigh University, reflecting the interdisciplinary mindset he now applies to one of the hardest engineering challenges in the world: making fusion power a commercial reality.#fusionenergy #fusion #cleanenergy #nuclearfusion #stellarator #tokamak #science #energy #futureofenergy #deeptech #climatechange #renewableenergy #hightech #engineering #superconductors #HTS #fusionpower #energytransition #cleantech #futuretech #startup #innovation #sciencepodcast #energyindependence #decarbonization #physics #bigideasSupport the show

Send us Fan MailWe're living through a golden age of rare disease breakthroughs—but for many patients, the hardest part begins after the drug is approved.Today we're joined by two leaders from the multinational biopharmaceutical company UCB ( https://www.ucb.com/ ) who are helping reshape how the rare disease community thinks about what happens after a therapy is approved—because for many families, approval is just the beginning of the journey.Dr. Kim Moran, Ph.D. is Senior Vice President and Head of U.S. Rare Diseases at UCB ( https://www.ucb-usa.com/UCB-in-the-U-S/U-S-Leadership-Team/Kim-Moran ). Dr. Moran leads the company's U.S. rare disease portfolio strategy and commercial organization, integrating clinical, regulatory, operational, and digital capabilities to bring therapies to patients with devastating and often ultra-rare conditions. Trained as a neuroscientist with a PhD from NYU and an Executive MBA from INSEAD, she has spent nearly two decades at UCB translating patient insights into real-world solutions—from epilepsy portfolio strategy to leading the recent FDA approvals and launches of two major rare disease assets. Dr. Moran is widely recognized for her leadership in the industry, including honors from the Healthcare Businesswomen's Association and Medical Marketing + Media, and she remains deeply focused on ensuring scientific breakthroughs actually translate into meaningful impact for patients and families.Brad Chapman is Head of U.S. Epilepsy and Rare Syndromes at UCB ( https://www.ucb-usa.com/UCB-in-the-U-S/U-S-Leadership-Team/Brad-Chapman ). Mr. Chapman oversees one of the deepest portfolios of anti-seizure therapies in the industry, including BRIVIACT, NAYZILAM, and FINTEPLA, while leading nationwide teams focused on connecting patients with both treatment and support systems. Over more than 15 years with UCB, Mr. Chapman has helped pioneer new go-to-market models in neurology that move decision-making closer to patients and providers, strengthen partnerships with the epilepsy community, and rethink how pharmaceutical organizations deliver value “beyond the pill.”Together, Dr. Moran and Mr. Chapman sit at the intersection of scientific innovation, patient access, and community infrastructure, and they're helping answer a critical question in rare disease: How do we make sure life-changing therapies actually reach—and work for—the patients who need them most?Important Episode Link - Caring for Adults with Rare Epilepsy -https://www.ucb-usa.com/sites/default/files/2024-06/UCBCAREBinder.pdf#RareDisease #UltraRareDisease #Epilepsy #CDKL5 #DravetSyndrome #RareEpilepsy #Biotech #Pharma #DrugDevelopment #PrecisionMedicine #Geroscience #HealthcareInnovation #PatientAccess #CaregiverSupport #MedicalInnovation #Neuroscience #MitochondrialDisease #TK2Deficiency #ClinicalTrials #LifeSciences #Biopharma #HealthPolicy #FutureOfMedicine #PatientCare #InnovationSupport the show

Send us Fan MailWhether it's a battlefield, a construction site, or a farm, the challenge is the same: how do you turn massive amounts of visual data into fast, accurate decisions? Increasingly, the answer is autonomous systems. transforming how we see the world—turning raw imagery into decisions at unprecedented speed.Bill Irby is CEO and Board Member of EagleNXT ( https://eaglenxt.com/ ), a leading provider of full-stack drone, sensor, and software solutions serving both commercial and government customers worldwide.Bill brings more than 25 years of leadership experience across the unmanned systems and defense technology landscape, spanning ISR (Intelligence, Surveillance, and Reconnaissance) platforms, communications systems, and advanced autonomy. Prior to EagleNXT, Bill held senior executive roles across some of the most important defense companies in the world, including serving as President of Reconnaissance Mission Systems at L3Harris Technologies, where he led a $1.5 billion portfolio supporting some of the U.S. military's most critical airborne intelligence platforms.Bill also served as Senior Vice President and General Manager of Unmanned Systems at Textron Systems, overseeing globally deployed UAV and unmanned maritime systems, and held multiple leadership roles at Northrop Grumman, focusing on C4ISR (Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance) and tactical communications.Earlier in his career, Bill served as a Combat Engineer in the United States Marine Corps, leading missions across the globe.In addition to his operational leadership, Bill has played a key role in shaping the unmanned systems ecosystem serving as Chairman of the Board of AUVSI ( Association for Uncrewed Vehicle Systems International - https://www.auvsi.org/ ), advocating for the safe integration and advancement of autonomous technologies.Bill is a graduate of the United States Naval Academy, holds a master's degree from Johns Hopkins University, and completed executive education at Harvard Business School.#DefenseTech #DroneWarfare #AutonomousSystems #MilitaryDrones #ISR #ArtificialIntelligence #FutureOfWar #UncrewedSystems #Aerospace #NationalSecurity #Robotics #AI #MilitaryTechnology #Innovation #TechPodcast #EmergingTech #BattlefieldTechnology #Surveillance #Geopolitics #StartupDefenseSupport the show

Send us Fan MailPreventing transplant loss doesn't just save organs—it could eliminate hospitalizations, reduce lifelong medications, and transform millions of lives.Dr. Janine Gaiha-Rohrbach, Ph.D. is a globally recognized leader in immunology and medical strategy, currently serving as Head of Global Medical Immunology at Biogen ( https://www.biogen.com/ ). With a PhD in Immunology and Virology from the University Hospital of Berne and extensive postdoctoral research at the Ragon Institute of Mass General Brigham, MIT, and Harvard, Dr. Gaiha-Rohrbach has dedicated her career to translating complex scientific advances into high-impact patient care.Throughout her career, Dr. Gaiha-Rohrbach has driven innovation across diverse therapeutic areas, including HIV, hepatitis, NASH, and specialized immunology, leading multiple new product launches and shaping global strategies to expand patient access.At Biogen, Dr. Gaiha-Rohrbach now focuses on advancing therapies in immunology with an emphasis on areas of high unmet need, including the evolving field of kidney transplantation.On today's episode, we'll explore the future of kidney transplant care, the limitations of current treatments for antibody-mediated rejection, and how emerging therapies targeting the immune system are poised to transform patient outcomes.#KidneyTransplant #TransplantInnovation #Biogen #Immunology #AntibodyMediatedRejection #AMR #CD38 #Felzartamab #OrganTransplant #HealthcareInnovation #Biotech #DrugDevelopment #PrecisionMedicine #Nephrology #ChronicKidneyDisease #MedicalBreakthrough #FutureOfMedicine #Immunotherapy #TransplantMedicine #LifeSavingScience #Podcast #HealthcarePodcast #BiotechPodcast #SciencePodcastSupport the show

Send us Fan MailPharma has spent decades building a graveyard of failed drugs — but hidden inside that data may be treatments that actually worked… for someone.Vin Singh is Founder and CEO of BullFrog AI ( https://bullfrogai.com/ ), a company working at the intersection of machine learning, causal modeling, and drug development.BullFrog is focused on a fundamental problem in biopharma — not just how to analyze increasingly large datasets, but how to extract meaningful cause-and-effect relationships from them. Their platform integrates data preparation, analysis, and network-based modeling to help research teams better understand biological mechanisms, identify patient subgroups, and improve clinical trial design.Vin brings a deep mix of technical, operational, and entrepreneurial experience to this challenge. Prior to founding BullFrog, he held leadership roles across the life sciences ecosystem, including serving as Global Director of the Cell Therapy Business at Thermo Fisher Scientific, where he oversaw services supporting clinical and commercial-stage therapies. He also founded and led Next Healthcare, a company focused on adult stem cell and skin cell banking, and was an early co-founder at MaxCyte, helping build foundational technologies in cell engineering.In addition to his operating roles, Vin has been active in the innovation ecosystem as a Mentor in Residence at Johns Hopkins Technology Ventures.Vin holds an MBA in Finance from Johns Hopkins University, a Master's in Biomedical Engineering from Rensselaer Polytechnic Institute, and a Bachelor's in Electrical Engineering from Rutgers University — a background that spans engineering, biology, and business.#CausalAI #DrugDevelopment #Biotech #ClinicalTrials #PrecisionMedicine #AIinHealthcare #PharmaInnovation #FailedDrugs #OncologyResearch #PancreaticCancer #FutureOfMedicine #MachineLearning #Biopharma #TranslationalMedicine #DigitalHealth #MedicalInnovation #DataScience #ClinicalResearch #AIinBiotech #HealthcareInnovationSupport the show

Send us Fan MailBone marrow transplants have always depended on finding the right donor at the right time. But what if bone marrow could be stored, shipped, and used on demand—just like a drug? That's exactly what Ossium Health is now showing in human clinical data.Kevin Caldwell is the Co-Founder, CEO, and President of Ossium Health ( https://ossiumhealth.com/ ), a clinical-stage bioengineering company pioneering off-the-shelf, cryopreserved bone marrow therapies derived from deceased organ donors.Under Kevin's leadership, Ossium has developed a novel platform designed to solve one of the most persistent challenges in transplantation medicine: timely access to compatible bone marrow for patients with life-threatening hematologic malignancies such as Acute Myeloid Leukemia. The company's approach enables on-demand delivery of viable marrow cells, bypassing the logistical and biological constraints of traditional donor matching and scheduling.Since its founding, Kevin has scaled Ossium from an early-stage startup into a clinical-stage company with a robust network of over 50 strategic partnerships across supply, clinical development, and commercial channels. He has led multiple financings and secured a landmark contract with the Biomedical Advanced Research and Development Authority, validating Ossium's relevance to national health preparedness and biomanufacturing resilience.Most recently, Kevin has overseen the company's transition into human clinical validation, including first-in-human data from the PRESERVE I trial, real-world use cases in transplant rescue scenarios, and peer-reviewed publication of its GMP-based manufacturing platform and early outcomes.Prior to founding Ossium, Kevin was an Engagement Manager at McKinsey & Company, advising biotech and healthcare companies on strategy, M&A, and restructuring. Earlier, he worked in quantitative research at Bridgewater Associates. He holds degrees in Physics and Economics from MIT and a JD from Harvard Law School.#Biotech #BoneMarrowTransplant #StemCells #CancerTreatment #Leukemia #AML #CellTherapy #RegenerativeMedicine #Biotechnology #FutureOfMedicine #HealthcareInnovation #MedicalBreakthrough #Immunotherapy #TransplantMedicine #Cryopreservation #LongevityScience #Bioengineering #StartupScience #OnDemandMedicine #PrecisionMedicine #ClinicalTrials #Biopharma #DeepTech #LifeSciences #HealthcareDisruptionSupport the show

Send us Fan MailThere's an entire medical specialty, Physiatry, dedicated not to treating disease - but to helping patients regain their lives. And most people have never heard of it.Dr. Michael Yochelson is a Physiatrist and a nationally recognized leader in rehabilitation medicine and brain injury care ( https://shepherd.org/staff-directory/michael-yochelson/ ).Dr. Yochelson serves as the Chief Medical Officer at Shepherd Center, one of the top hospitals in the United States for spinal cord and brain injury rehabilitation. He is also an Adjunct Professor at Emory University School of Medicine ( https://med.emory.edu/directory/profile/?u=MYOCHEL ).Board-certified in both neurology and physical medicine & rehabilitation, Dr. Yochelson has spent decades at the forefront of helping patients recover from some of the most complex neurological injuries. Prior to Shepherd Center, he held major leadership roles at MedStar National Rehabilitation Network and Georgetown University, where he also founded and led a Brain Injury Medicine Fellowship program.Earlier in his career, Dr. Yochelson served for over a decade in the United States Navy, including leadership roles in neurology and rehabilitation medicine.In addition to his clinical and academic work, Dr. Yochelson serves on the Board of Governors of the American Academy of Physical Medicine and Rehabilitation ( https://www.aapmr.org/ ), where he chairs the Inclusion and Engagement Committee, helping shape the future of a specialty dedicated not just to treating disease—but restoring function, independence, and quality of life.Important Episode Link - Understanding Spasticity: A Simple Guide to Symptoms, Treatment, and Getting Better - https://www.aapmr.org/resources/AAPMR_Spasticity_Patient_Journey.html#Physiatry #RehabilitationMedicine #AAPMR #Neurorehabilitation #BrainInjury #StrokeRecovery #SpinalCordInjury #Mobility #Function #QualityOfLife #Neuroplasticity #RecoveryScience #FutureOfMedicine #HealthcareInnovation #PatientRecovery #DisabilityCare #HumanPerformance #Longevity #MedicinePodcast #HealthPodcast #SciencePodcast #ClinicalInnovation #MedicalEducation #RestoreFunctionSupport the show

Send us Fan MailLyme disease affects hundreds of thousands of people every year—and yet we still struggle to diagnose it, treat it, and prevent it.David Walsey is a strategic biotech leader with more than two decades of experience helping public life sciences companies translate scientific innovation into market impact. As Executive Director of the Bay Area Lyme Foundation ( https://www.bayarealyme.org/ ), David leads national efforts to accelerate research, improve diagnostics, and expand access to effective treatments for Lyme disease and other tick-borne illnesses—an area of growing public health urgency.Prior to joining the Foundation, David served as Senior Vice President of Corporate Affairs at MEI Pharma, where he oversaw corporate strategy, investor relations, and communications during a critical period for the company. His career spans leadership roles across the biotech ecosystem, including Alder Biopharmaceuticals, Optimer Pharmaceuticals, Sarepta Therapeutics, Arena Pharmaceuticals, and Maxim Pharmaceuticals, as well as strategic communications roles at agencies such as Real Chemistry (formerly W2O Group), The Ruth Group, and Noonan Russo.David began his professional journey as a practicing attorney in New York City, bringing a legal and financial lens to his later work in biotech leadership. He holds an LL.M. in Taxation from New York University School of Law, a J.D. from Brooklyn Law School, and a B.A. from Franklin and Marshall College.#LymeDisease #LymeVaccine #Pfizer #Biotech #VaccineScience #PublicHealth #TickBorneDisease #MedicalInnovation #Biotechnology #Healthcare #InfectiousDisease #ClinicalTrials #VLA15 #Pharma #DrugDevelopment #SciencePodcast #Longevity #Diagnostics #VenturePhilanthropy #BayAreaLyme #FutureOfMedicine #BioInnovation #HealthcareInnovation #MedicalResearchSupport the show

Send us Fan MailFor decades, male birth control has remained one of medicine's most elusive goals. Now, a new non-hormonal pill is entering human trials—and could finally change the balance of reproductive responsibilityAkash Bakshi is CEO and Co-Founder of YourChoice Therapeutics ( https://www.yourchoicetx.com/ ), a company working to develop the first hormone-free birth control pill for men.Akash's work sits at the intersection of biotechnology innovation, reproductive health, and social change. His team is advancing YCT-529, a first-in-class non-hormonal contraceptive currently in human clinical trials, designed to safely and reversibly suppress sperm production by targeting retinoic acid signaling.Before founding YourChoice, Akash held leadership roles across biotech and drug development, including serving as CEO of ANA Therapeutics, where he rapidly advanced a COVID-19 therapeutic into clinical trials and led the company through acquisition, as well as COO of NeuroBo Pharmaceuticals.Earlier in his career, Akash worked at University of California, Berkeley helping bridge early-stage science and commercialization—experience that clearly shaped his approach to translating breakthrough academic research into real-world therapies.At a time when contraceptive responsibility has largely fallen on women—and amid growing debates around reproductive rights—Akash and his team are trying to fundamentally reshape the landscape.#MaleBirthControl #BirthControlPillForMen #NonHormonalContraception #YCT529 #BiotechBreakthrough #FutureOfMedicine #ReproductiveHealth #MensHealth #WomensHealth #FertilityScience #PharmaInnovation #ClinicalTrials #BiotechStartups #HealthcareInnovation #EndUnintendedPregnancy #SciencePodcast #LongevityAndHealth #DrugDevelopment #MedicalBreakthrough #ContraceptionRevolution #FutureOfHealthcare #RARalpha #YourChoiceTherapeutics #BiotechCEO #HealthTech #PostRoeWorldSupport the show

Send us Fan MailThere's an animal that can rebuild its entire body structure in just a few days—and it might hold clues to a new kind of medicine.Eden Ben is CEO of Amorphical ( https://www.amorphical.com/ ), a pioneering biotech company out of Israel that's been quietly building a completely new approach to mineral-based therapeutics.Founded in 2004, Amorphical has developed a proprietary nano-formulation of amorphous calcium carbonate—what they call ACC—engineered using biomimicry principles inspired by how certain organisms naturally stabilize calcium in highly bioavailable forms.What makes this so interesting is that ACC behaves very differently from traditional crystalline calcium. It's dramatically more soluble, significantly more bioavailable, and appears to act not just as a supplement, but as a functional, bioactive material that can influence cellular and tissue-level processes.The company is leveraging this platform across a range of indications—from bone and metabolic diseases to inflammatory conditions—aiming to move beyond symptom management and toward addressing underlying biological mechanisms.Eden himself has had a fascinating journey with the company—from early business development and global market expansion, to leading clinical and product strategy, and now stepping into the CEO role to scale both the science and the business globally.#Biotech #Longevity #Geroscience #Calcium #Nanotechnology #Biomimicry #ExtracellularMatrix #CancerResearch #Inflammation #Osteoporosis #BoneHealth #FutureOfMedicine #LifeSciences #Biology #RegenerativeMedicine #HealthInnovation #StartupScience #DeepTech #MedicalBreakthrough #Podcast #SciencePodcast #IsraeliInnovation #NanoMedicine #AgingResearchSupport the show

Send us Fan MailWhat if AI didn't need massive data centers—and could think more like the human brain?Sean Hehir is the Chief Executive Officer of BrainChip ( https://brainchip.com/ ), a pioneer in neuromorphic computing and ultra-low-power artificial intelligence hardware designed for intelligent edge devices.At BrainChip, Sean oversees the commercialization of the company's Akida neuromorphic processor—an advanced AI chip inspired by the architecture of the human brain. Akida enables real-time machine learning and pattern recognition directly at the edge, dramatically reducing power consumption and latency compared to traditional cloud-based AI systems. The technology is now being explored for applications ranging from defense and autonomous systems to automotive sensing, robotics, and healthcare devices.Prior to joining BrainChip in 2021, Sean spent more than two decades in senior leadership roles across the enterprise computing and semiconductor ecosystem. Earlier in his career, Sean held several senior executive roles at Hewlett‑Packard, including Vice President of Strategic Alliances, where he managed some of the company's most important global partnerships with industry giants such as Microsoft, Intel, Cisco Systems, Oracle, and SAP.His earlier leadership experience also includes roles at Fusion‑io and Compaq, where he helped drive large-scale enterprise computing partnerships and global service provider strategies.Sean holds an MBA in Economics from Georgia State University and a Bachelor of Science in Business from University of Massachusetts Amherst.#AI #ArtificialIntelligence #NeuromorphicComputing #BrainInspiredAI #EdgeAI #FutureOfAI #AIHardware #TechInnovation #DefenseTech #AutonomousSystems #MachineLearning #DeepLearning #NextGenAI #QuantumComputing #Semiconductors #Robotics #SmartSensors #AIRevolution #EmergingTech #HealthcareAI #WearableTech #MilitaryTechnology #Innovation #FutureTech #PodcastSupport the show

Send us Fan MailNorberto Chaclin is Executive Vice President, Chief Research & Development Officer of Mondelēz International ( https://www.mondelezinternational.com/about-us/leadership/executive-team/norberto-chaclin/ ), a global snacking leader with 2025 net revenues of approximately $38.5 billion, driven by iconic brands such as Oreo, Ritz, LU, Clif Bar and Tate's Bake Shop biscuits and baked snacks, as well as Cadbury Dairy Milk, Milka and Toblerone chocolate. Norberto most recently served as the Company's Senior Vice President, R&D, Global Biscuits and Regional R&D partner for North America. Under his leadership, Mondelēz rolled out exciting innovations and renovations across some of its most iconic biscuit and baked snack brands. Previously, he led R&D for the Company's global gum and candy business. Before joining Mondelēz International, Norberto spent 18 years with PepsiCo in a series of progressively responsible roles spanning Frito-Lay North America, PepsiCo International, Global Beverages and Joint Ventures – ultimately leading R&D for PepsiCo North America Beverages and the Pepsi/Starbucks joint venture. An amateur chef and native of Curaçao, Netherlands Antilles, Norberto brings to the role a passion for culinary arts and traditions. He holds a bachelor's degree in chemical engineering from Texas A&M University and a master's degree in business administration from Southern Methodist University. He serves on the Board of Torr FoodTech and on the Board of Trustees for IAFNS – Advancing Food and Nutrition Sciences.Important Episode Link Mondelēz International's State of Snacking reports - https://www.mondelezinternational.com/stateofsnacking/#FutureOfFood #FoodTech #Snacking #Mondelez #Oreo #Cadbury #Chocolate #FoodInnovation #CPG #FMCG #AI #PrecisionFermentation #Sustainability #HealthySnacks #FoodScience #ConsumerTrends #GenZ #SupplyChain #FoodFuture #InnovationSupport the show

Send us Fan MailModern warfare is changing—and it's not just about weapons anymore.The real battle may be logistics, and autonomous systems are about to transform how wars are fought and sustained.Brandon Florian is Co-Founder and Chief Commercial Officer of Grid Aero ( https://www.grid.aero/ ), a venture-backed aerospace and defense startup building low-cost, autonomous aircraft designed for long-range operations and resilient logistics.Brandon has spent more than two decades working at the intersection of aerospace engineering, national security strategy, and emerging defense technologies. His career spans engineering, business development, and technology scouting across both large defense primes and the startup ecosystem.Brandon began his career as a spacecraft engineer at General Dynamics working on space systems before moving into strategic roles at Northrop Grumman, where he focused on innovation, disruptive technology scouting, and growth strategy. He later joined Starburst Aerospace, one of the leading global accelerators for aerospace and defense startups, where he helped build international innovation programs—including collaborations between the U.S. Space Force and the UK Ministry of Defense.Brandon has also worked extensively in venture and startup ecosystems through Mandala Space Ventures and independent consulting, helping governments and corporations navigate the rapidly evolving landscape of defense innovation.Today at Grid Aero, Brandon is focused on a critical challenge shaping modern warfare: how to build resilient logistics networks capable of operating in contested environments using autonomy, distributed systems, and radically lower-cost platforms.With a background in aerospace engineering from UCLA and an MBA from Pepperdine, Brandon brings both technical depth and strategic insight into how emerging technologies—from autonomous aircraft to distributed supply networks—will shape the future of defense operations.#defensetech #militaryinnovation #futureofwar #autonomy #AI #nationalsecurity #military #aerospace #drones #logistics #warstrategy #china #taiwan #iran #pentagon #startups #innovation #technology #supplychain #geopoliticsSupport the show

Send us Fan MailAdam Molnar is Co-Founder, COO and Vice President of Strategic Partnerships at Neurable ( https://www.neurable.com/ ), a pioneering neurotechnology company developing real-time brain-computer interface systems that translate neural signals into actionable insights.Over the past decade, Adam and his team have been working at the frontier of non-invasive EEG-based brain-computer interfaces, building technology capable of measuring cognitive states such as workload, fatigue, and attention directly from brain activity. Neurable's platform has attracted over $40 million in funding and has led to collaborations with organizations including the U.S. Air Force, the Air Force Research Laboratory, and U.S. Army, where the technology is being evaluated for applications ranging from pilot training and human performance monitoring to the detection of blast-related mild traumatic brain injury.Adam leads the company's global strategic partnerships across both commercial and defense sectors, helping bring neurotechnology out of the lab and into real-world environments—from wearable computing platforms to operational military systems. His work sits at the intersection of AI, neuroscience, and human-machine teaming, exploring how brain data can improve safety, cognition, and performance in high-stakes environments.Beyond Neurable, Adam contributes to the global neurotechnology ecosystem through organizations like NeuroTechX and the Institute of Neuroethics, helping shape the future of neural data governance and ethical brain-computer interfaces. He has also been recognized as part of Forbes 30 Under 30 for his work in advancing consumer neurotechnology.Today we'll explore how brain-computer interfaces are moving beyond laboratories and into operational systems—from defense training environments to everyday wearable devices—and what it means when machines can finally begin to understand the human brain in real time.#neurotechnology #BCI #artificialintelligence #futuretech #wearables #braincomputerinterface #AI #defensetech #militaryinnovation #humanperformance #neuroscience #neuroethics #emergingtechnology #innovation #podcast #techtalk #longevity #healthtech #digitalhealth #futureofworkSupport the show

Send a textGreg Fallon is the CEO of Geminus AI ( https://www.geminus.ai/ ), a company developing real-time, physics-native artificial intelligence designed to operate complex industrial and energy systems. His work focuses on combining engineering simulation, machine learning, and physical laws to create AI systems that can reason about and optimize real-world infrastructure under uncertainty.Before founding Geminus AI, Greg held leadership roles at Autodesk and Ansys, two of the world's leading platforms for digital engineering and simulation. Across more than two decades in industrial technology, he has worked at the intersection of computational physics, engineering software, and AI.At Geminus AI, Greg and his team are building a new class of industrial intelligence platform that allows machines to model their own behavior and make operational decisions in real time—potentially transforming how critical infrastructure such as energy systems, manufacturing plants, and industrial networks are designed, operated, and optimized.#ArtificialIntelligence #IndustrialAI #EngineeringAI #PhysicsAI #EngineeringSuperintelligence #FutureOfAI #DigitalTwins #EnergyTechnology #InfrastructureInnovation #AIRevolution #TechnologyPodcast #EngineeringInnovation #DeepTech #FutureOfEngineering #AIForIndustrySupport the show

Send a textArtificial intelligence and robotics are rapidly transforming surgery. In this episode we explore the future of the operating room with Medtronic's vision for the AiBLE ecosystem and the newly cleared Stealth AXiS surgical platform — technologies designed to integrate surgical planning, navigation, robotics, and real-time intelligence into a single system.Vignesh Shetty is Vice President of AI and Product Development at Medtronic Cranial and Spine Therapies, where he leads the convergence of AI, Robotics, and R&D for the company's $6B Cranial and Spine portfolio, with objectives of moving beyond standalone devices to create intelligent procedural ecosystems to redefine the standard of care ( https://www.medtronic.com/en-us/index.html ).Leading a global team of 900+ across Software and R&D, Mr. Shetty bridges the gap between complex engineering and clinical reality, building AI-enabled platforms across robotics, imaging, planning and implants biologics to drive impact across Medtronic' 3Es -Efficiency: Streamlining surgical workflows through automation.Efficacy: Enhancing clinical precision with data-driven insights.Experience: Elevating the human element for both surgeons and patients.Prior to joining Medtronic, Mr. Shetty served as Senior Vice President and General Manager of Edison AI and Platform at GE Healthcare, where he led a team of 700+ engineers and product managers to deliver cutting-edge AI solutions for healthcare imaging, diagnostics, and workflow optimization.Mr. Shetty also previously spent 16 years holding diverse roles at Cisco. His career is marked by his passion for developing technical talent and empowering teams, which has resulted in double-digit growth across multiple revenue streams. Important Episode Links AiBLE™ Smart Ecosystem - https://www.medtronic.com/en-us/healthcare-professionals/specialties/spinal-cranial-orthopedic/therapies-procedures/technology-ai-driven-surgery/aible-smart-ecosystem.html Stealth AXiS™ Surgical System - https://www.medtronic.com/en-us/healthcare-professionals/specialties/spinal-cranial-orthopedic/therapies-procedures/technology-ai-driven-surgery/discover-the-stealth-axis-surgical-system.html#AIinMedicine #RoboticSurgery #FutureOfSurgery #MedTech #HealthcareInnovation #AISurgery #MedicalTechnology #SurgicalRobotics #DigitalHealth #FutureOfMedicine #SpineSurgery #AIHealthcare #MedicalInnovationSupport the show

Send a textDr. Javad Shabani, Ph.D. ( https://as.nyu.edu/faculty/javad-shabani.html ) is Professor of Physics; Director of the Center of Quantum Information Physics ( https://as.nyu.edu/departments/physics/research/center-for-quantum-information-physics.html ); Director of the NYU Quantum Institute; and member of the Affiliated Faculty, NYU-Korea Advanced Institute of Science and Technology Global Innovation and Research Institute ( https://www.nyu.edu/research/nyu-kaist.html ).Dr. Shabani's team of engineers is focused on building hybrid semiconductor–superconductor systems designed to make quantum bits — or qubits — more stable, scalable, and ultimately practical.Dr. Shabani's work ( https://wp.nyu.edu/shabanilab/ ) sits at the intersection of materials science, condensed matter physics, and quantum engineering — and could determine whether quantum computing becomes a transformative technology for medicine, materials discovery, cryptography, and beyond.Dr. Shabani received his Ph.D. from Princeton University in 2011. After two years of research on semiconductor-based qubits at Harvard University, he joined UC Santa Barbara. There, he worked closely with Microsoft research on hybrid semiconductors/superconductors heterostructures to study topological superconductivity. Dr. Shabani is also Co-Founder and CSO of QuantumMatter Inc. ( https://quantummatter.com/ ), a quantum hardware startup developing high-performance components that will power the next generation of quantum tech.#QuantumComputing #QuantumPhysics #QuantumTechnology #QuantumHardware #Majorana #TopologicalQubits #QuantumMaterials #QuantumDevices #QuantumSensing #QuantumCommunication #QuantumInternet #SuperconductingQubits #CondensedMatterPhysics #FutureOfComputing #NYUResearch #QuantumInnovationSupport the show

Send a textTara Austraat-Churik is a Partner at Blue Matter ( https://bluematterconsulting.com/ ), a strategic consulting firm serving the life sciences industry, bringing new approaches to consulting with original ideas that deliver a meaningful impact. Tara began her career as a counterterrorism intelligence analyst at the Federal Bureau of Investigation, where she prepared strategic assessments for senior policymakers, Cabinet officials, and members of the intelligence community. Trained in structured analytic tradecraft and foreign denial and deception, she worked in environments defined by incomplete information, high stakes, and institutional bias.Tar would later bring that analytical lens into the life sciences sector — first at IBM Watson Health during the early wave of AI in drug discovery, where she led major enterprise partnerships with global pharmaceutical companies. From there she went on to senior leadership roles at EY, advising C-suite leaders on R&D transformation, innovation ecosystems, and AI-driven operating model redesign.Tara has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. Today, as a Partner at Blue Matter, Tara is building the firm's first dedicated R&D strategy and transformation practice. Blue Matter has advised more than 320 biopharma clients — including 18 of the top 20 global pharmaceutical companies — and has supported more than 300 therapies across the molecule-to-market continuum.Tara holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh.#AIinPharma #DrugDiscovery #BiotechInnovation #PharmaR&D #ArtificialIntelligence #HealthcareAI #FutureOfScience #BiotechPodcast #RareDiseaseResearch #PharmaStrategy #HumanAI #ConsultingCareers #DrugDevelopment #LifeSciences #TechInHealthcareSupport the show

Send a textFor most of the history of computing, software systems were written by humans and—at least in theory—understood by humans.But with AI coding assistants now embedded in everyday development workflows, we may be entering an era where large portions of production software are generated, modified, and extended by machines.Pramin Pradeep is the Co-Founder and CEO of BotGauge ( https://www.botgauge.com/ ), an autonomous “QA-as-a-Solution“ company focused on using AI to improve software testing and observability in modern development environments.Pramin's background sits at the intersection of AI-driven development and quality assurance. Prior to founding BotGauge, he held product leadership roles at Sauce Labs, one of the leading platforms for automated testing and continuous quality in enterprise software. Earlier in his career he was a founding product leader at AutonomIQ, an AI-based low-code testing platform that was later acquired by Sauce Labs.Across these roles, Pramin has focused on a central challenge in modern software engineering: as development accelerates through automation and AI coding assistants like GitHub Copilot, Claude, and Gemini, organizations are increasingly deploying code that no single engineer fully understands.Pramin's work explores how this emerging layer of AI-generated logic—what some are calling “shadow code”—may introduce new security risks, operational blind spots, and governance challenges inside complex software systems.Today we'll talk about what happens when software systems start evolving faster than our ability to fully comprehend them.#AI #AICoding #ShadowCode #BotGauge #SoftwareSecurity #Cybersecurity #EnterpriseSoftware #AIgeneratedCode #RuntimeObservability #SoftwareTesting #CriticalInfrastructure #TechnicalDebt #AIrisks #TechLeadership #InnovationSupport the show

Send us Fan MailKabir Nath is Chief Executive Officer of Compass Pathways  ( https://compasspathways.com/ ), a biotechnology company pioneering evidence-based psychedelic innovation for serious mental health conditions.Kabir brings nearly three decades of leadership experience across the biopharmaceutical and medical device industries. Before joining Compass, he served as Senior Managing Director of Global Pharmaceuticals at Otsuka Pharmaceutical Co., and previously as President and CEO of Otsuka's North America Pharmaceutical Business, where he led the development of therapies and digital solutions addressing complex mental health needs. Earlier in his career, he held senior leadership roles at Bristol Myers Squibb.Under Kabir's leadership, Compass has advanced COMP360 — a synthetic, proprietary formulation of psilocybin — through two pivotal Phase 3 trials in treatment-resistant depression. The program has demonstrated statistically significant and clinically meaningful reductions in depression severity, potentially positioning COMP360 to become the first FDA-approved psilocybin-based treatment.Kabir holds an MA from the University of Cambridge and an MBA from INSEAD.#PsychedelicMedicine #Psilocybin #DepressionTreatment #MentalHealthInnovation #CompassPathways #COMP360 #TreatmentResistantDepression #Biotech #Neuroscience #FutureOfPsychiatry #ClinicalTrials #MentalHealthResearch #PsychedelicTherapy #BiotechInterview #DrugDevelopmentSupport the show

Send a textLacey Stone is Chief Development Officer at USA for UNHCR ( https://www.unrefugees.org/about-us/ ), the U.S. partner of United Nations High Commissioner for Refugees ( UNHCR - https://www.unhcr.org/ ), the UN Refugee Agency.UNHCR is a global organization dedicated to saving lives, protecting rights, and building better futures for refugees, forcibly displaced communities, and stateless people. It provides life-saving assistance (shelter, food, medical care) and works in over 130 countries to ensure safety and human rights, often deploying within 72 hours of a crisis.Lacey is a mission-driven leader with more than two decades of experience mobilizing partnerships, philanthropy, and storytelling to address some of the world's most urgent humanitarian challenges. In her role, she leads strategy across private philanthropy, corporate and foundation partnerships, and national engagement efforts that amplify refugee voices and generate critical support for displaced communities worldwide.Lacey's career spans influential leadership roles with organizations including UNICEF USA, PATH, and St. Jude Children's Research Hospital, where she built cross-sector collaborations advancing global health, children's wellbeing, and humanitarian response.Today's conversation will also focus on the Building Better Futures ( https://www.unrefugees.org/building-better-futures/ ) initiative — a women-led philanthropic effort supporting higher-education scholarships for refugee women and girls — and the broader movement redefining who gives, who benefits, and how philanthropy can drive lasting systemic change.Lacey holds an M.A. in International Relations from Villanova University and dual B.A. degrees in International Relations and Rhetoric & Communication from the University of Pittsburgh.#LaceyStone #USAforUNHCR #UNHCR #BuildingBetterFutures#RefugeeEducation #WomenLed #InternationalWomensDay#GlobalHealth #Rwanda #HumanitarianLeadership #WomenSupportingWomen #Philanthropy #SystemsChange#RefugeeWomen #ProgressPotentialPossibilitiesSupport the show

Send a textDr. Tomasz Beer, MD is a nationally recognized medical oncologist and clinical research leader who serves as Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation ( https://www.exactsciences.com/ ), a molecular diagnostics company focused on the eradication of cancer by preventing it, detecting it earlier, and guiding personalized treatment.Before joining Exact Sciences, Dr. Beer spent decades at the forefront of academic oncology, including serving as Deputy Director of the Oregon Health & Science University (OHSU) Knight Cancer Institute, where he helped build one of the country's leading precision cancer programs.A prostate cancer specialist by training, Dr. Beer has led numerous clinical trials, authored hundreds of peer-reviewed publications, and been a driving force in advancing biomarker-guided cancer therapy. His career has spanned the evolution of oncology—from empiric chemotherapy to precision medicine and now toward population-scale cancer detection.Today, Dr. Beer is helping lead one of the most ambitious shifts in cancer care: moving from late-stage treatment to early detection across multiple tumor types through advanced molecular diagnostics and blood-based screening technologies.#MultiCancerEarlyDetection #CancerInterception #LiquidBiopsy #PrecisionOncology #CancerPrevention #Immunotherapy #EarlyDetection #OncologyInnovation #CancerResearch #MCEDSupport the show

Send a textDr. Sharron Gargosky, Ph.D. is Chief Clinical Officer of Spinogenix, Inc. ( https://spinogenix.com/ ), a clinical-stage company pioneering a new class of therapeutics designed to reverse synaptic loss and dysfunction in the brain.Spinogenix is advancing two first-in-class oral small molecules. Tazbentetol is a synaptic regenerative therapy shown to regrow brain synapses — the vital connections between neurons. Clinical data have demonstrated rapid and significant improvements in memory and thinking in Alzheimer's disease, as well as clinically meaningful slowing of disease progression in ALS. The therapy is also being evaluated in schizophrenia, with a Phase 2 trial underway. Tazbentetol has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for ALS, and the company has established an Expanded Access Program to provide investigational treatment options to eligible ALS patients.Spinogenix's second program, SPG601, is a synaptic corrective therapy for Fragile X Syndrome — the leading inherited cause of intellectual disability and a known genetic driver of autism. Clinical data have shown normalization of abnormal brain activity patterns and improvements in attention and focus. SPG601 has received Orphan Drug and Fast Track Designations and is advancing toward late-stage development.Dr. Gargosky brings more than 25 years of global development leadership experience across small molecules, biologics, cell therapies, and diagnostics. She has overseen regulatory, CMC, non-clinical, clinical, and medical affairs programs across more than 15 countries, and has led multiple orphan and accelerated approval pathways.Previously, Dr. Gargosky held senior leadership roles at OncoSec Medical, Prima Biomed, Hyperion Therapeutics, Pfizer, and served in academia at Stanford University and Oregon Health & Science University.#Spinogenix #SynapticRegeneration #FragileX #AlzheimersResearch #ALSResearch #Neuroscience #BrainHealth #BiotechInnovation #Synaptopathy #ClinicalTrials #RegenerativeMedicine #Neurodevelopment #SharronGargoskySupport the show

Send a textPaul Woodward ( https://www.imdb.com/name/nm2813295/ ) is a filmmaker, storyteller, and advocate whose deeply personal work has touched audiences around the world.Paul is the producer of the feature documentary The Little Things ( https://www.youtube.com/watch?v=pZDDw4yYl_w ), a film that invites viewers behind the doors of Derian House Children's Hospice ( https://www.derianhouse.co.uk/ ) — not to witness sadness, but to witness love and the remarkable humanity that unfolds in the most challenging of circumstances.Inspired by his own experience as a parent, Paul began this project to say thank you to the hospice that cared for his son Kalel for seven years. What started as a personal tribute evolved into a powerful documentary that challenges common misconceptions about hospice care, celebrates the relationships between families and caregivers, and shows how places like Derian House become a bridge through grief — offering connection, compassion, and dignity when it's needed most.Since its release — including streaming on Amazon Prime — The Little Things ( https://www.primevideo.com/detail/The-Little-Things/0TOUFVXP6JTZZTM28LEA8TS19H ) has moved audiences with its honesty, heart, and belief that the smallest moments can reveal the deepest meaning.Paul now serves as a Patron of Derian House, continuing his mission to spark conversation, awareness, and empathy for families navigating the unthinkable.Paul holds an MA in Professional Acting from the Academy of Live and Recorded Arts (ALRA), has over ten years of work spanning TV, film, theatre, and UK tours, and co-owns Old Swan Films ( https://oldswanfilms.com/ ), a company that focuses on human stories with emotional honesty.We're honored to have Paul on the show to talk about the story behind the film, the lessons of love and presence he's learned along the way, and what it truly means to find light in life's hardest places.#TheLittleThings #ChildrensHospice #PaulWoodward#PediatricPalliativeCare #GriefAndLove #EndOfLifeCare#HospiceCare #Fatherhood #Bereavement #DocumentaryFilm #LifeAndLoss #CompassionSupport the show

Send a textDr. Allison Reiss, MD is an internal medicine physician, molecular biologist, and educator whose career sits at the critical intersection of inflammation, cardiometabolic disorders, and neurodegeneration.Dr. Reiss serves as Associate Professor of Medicine and Head of the Inflammation Laboratory at the NYU Grossman Long Island School of Medicine ( https://medli.nyu.edu/faculty/allison-b-reiss ).  She is also a Member of the Medical, Scientific & Memory Screening Advisory Board of the Alzheimer's Foundation of America.For more than 25 years, Dr. Reiss' research has explored how immune and metabolic dysfunction contribute to neuronal loss in Alzheimer's disease and accelerated atherosclerosis in conditions such as lupus, rheumatoid arthritis, and diabetes — helping illuminate the biological links between brain health, vascular disease, and aging.Clinically trained and board-certified in internal medicine, Dr. Reiss brings a rare translational perspective, connecting bedside observations with molecular mechanisms. Beyond the lab, she is a dedicated mentor and educator, directing translational research training for medical students and actively inspiring the next generation of clinician-scientists.Dr. Reiss' work has been recognized by organizations including the American Heart Association and the Alzheimer's Foundation of America, and she serves in editorial leadership roles across several journals focused on cardiovascular disease, aging, and neurodegeneration.On this episode, we explore the evolving science of neuroinflammation, the metabolic roots of Alzheimer's disease, and how understanding immune-brain-vascular crosstalk may unlock entirely new therapeutic strategies for aging populations.#AlzheimersDisease #Neuroinflammation #BrainHealth#DementiaPrevention #MetabolicHealth #VascularHealth#LongevityScience #Neurodegeneration #MedicalResearch #PhysicianScientistSupport the show

Send a textDr. Kevin Rynearson, Ph.D. is a medicinal chemist and translational neuroscientist focused on developing disease-modifying therapies for Alzheimer's disease.Over more than a decade, Dr. Rynearson's work has centered on the design and optimization of gamma-secretase modulators, an approach aimed at altering amyloid biology in a safer and more physiologically balanced way than earlier generations of therapies.During his time at the University of California San Diego School of Medicine, Dr. Rynearson helped advance mechanistic understanding of gamma-secretase activity, tau phosphorylation, and structure-activity relationships guiding next-generation Alzheimer's drug design.Dr. Rynearson currently serves as Chief Scientific Officer of Acta Pharmaceuticals ( https://www.linkedin.com/company/acta-pharmaceuticals/ ), where he leads development of a clinical-stage gamma-secretase modulator emerging from decades of collaborative research, including work with renowned Alzheimer's researcher Rudy Tanzi.In parallel, Dr. Rynearson is Head of Research at CogniSHIELD Global ( https://cognishield.com/ ), exploring preventative strategies and interventions aimed at supporting brain resilience and healthy cognitive aging.Dr. Rynearson's work sits at the intersection of medicinal chemistry, neurobiology, and preventive neurology — with a focus on shifting Alzheimer's treatment from late-stage symptom management toward early intervention and disease prevention. #AlzheimersDisease  #BrainHealth #Neurodegeneration #LongevityScience #CognitiveHealth #PreventAlzheimers #Neuroscience #BiotechPodcast #GammaSecretase #AmyloidBeta #Neuroinflammation #BrainAging #DementiaResearch #HealthyAging #TranslationalMedicine #DrugDevelopment #PrecisionMedicine #MemoryLoss #BrainResilience #FutureOfMedicineSupport the show

Send a textDr. Ben Hwang, Ph.D. is Chairman and CEO of Profusa ( https://profusa.com/ ), a pioneering bioengineering company developing tissue-integrated biosensors designed to continuously measure key chemical markers within the body. Profusa's mission is to make our body's chemistry as accessible as heart rate or step count — transforming personal and societal health through real-time molecular insight.Dr. Hwang has spent his career at the frontier where life science tools, digital systems, and global markets intersect. As an undergraduate research fellow in the laboratory of systems biology pioneer Leroy Hood at California Institute of Technology, he witnessed firsthand how transformative technologies can redefine biology.Dr. Hwang later held multiple senior leadership roles at Life Technologies (now part of Thermo Fisher Scientific), including President of Asia Pacific and Head of the qPCR Division — helping scale molecular biology platforms globally during a pivotal period for genomics and diagnostics.Earlier in his career, Dr. Hwang worked at McKinsey & Company and even began in professional sports with the Los Angeles Dodgers — an unusual trajectory that informs his leadership perspective today.Dr. Hwang earned his M.A. and Ph.D. in Biology from Johns Hopkins University.#DigitalHealth #Longevity #Biosensors #ContinuousMonitoring #FutureOfMedicine #HealthcareInnovation #WearableTech #Biotechnology#PrecisionMedicine #HumanOptimization #HealthTech #PreventiveMedicine#AgingResearch #Biohacking #MedicalInnovation #MetabolicHealth #Hypoxia #Mitochondria #ChronicDisease #FutureOfHealthcareSupport the show

Send a textThomas Hamilton is a Board Director Friedreich's Ataxia Research Alliance   ( FARA - https://www.curefa.org/ ), Co-Founder of the CureFA Foundation ( https://curefafoundation.org/ ), which supports diverse and innovative research strategies aimed at curing the disease, and the Founder of FA212, LLC, an organization pursuing a novel gene therapy strategy designed to address both central nervous system and systemic manifestations of FA.Thomas' journey into rare disease advocacy began not in a laboratory, but at home when in 2013, his nine-year-old daughter Annie was diagnosed with Friedreich's Ataxia — a rare, progressive neuromuscular disorder that affects balance and coordination and can lead to scoliosis, diabetes, sensory loss, and serious cardiac complications. Friedreich's ataxia (FA) is a rare, inherited, progressive neurodegenerative disorder caused by a mutation in the FXN gene, which leads to a deficiency of the frataxin protein.Like many families facing a rare diagnosis, the Hamilton family was suddenly thrust into a world of uncertainty, limited treatment options, and an urgent need for answers.Rather than accept the status quo, Thomas made the life-altering decision to step away from his professional career and dedicate himself fully to accelerating therapeutic progress for FA.Thomas joined the executive leadership of the Friedreich's Ataxia Research Alliance (FARA), where he remains an active board member, and co-founded the CureFA Foundation to support diverse and innovative research strategies aimed at curing the disease.In 2014, working alongside family members and clinical partners, Tom helped establish an FA Center of Excellence at Children's Hospital of Philadelphia  ( https://www.research.chop.edu/friedreichs-ataxia-center-of-excellence ) in collaboration with University of Pennsylvania — creating a dedicated clinical and research hub for patients and scientists focused exclusively on Friedreich's Ataxia. Driven by the belief that bold approaches were needed, Thomas also founded FA212, LLC to pursue a novel gene therapy strategy designed to address both central nervous system and systemic manifestations of FA. That program has evolved into SGT-212, now being advanced by Solid Biosciences ( https://www.solidbio.com/our-science/pipeline-programs/pipeline/ ).The therapy has entered human clinical evaluation through the FALCON study ( https://clinicaltrials.gov/study/NCT07180355 ), with the first participant recently dosed at Ohio State University Wexner Medical Center — marking a milestone not only for the Hamilton family but for the broader FA community.Today, Annie is 19 and a student at University of Notre Dame, living with FA while witnessing firsthand the progress her family helped catalyze.Thomas and Annie's story represents the growing power of parent-driven innovation in rare disease — where urgency, collaboration, and perseverance can reshape the therapeutic landscape.#FriedreichsAtaxia #RareDisease #GeneTherapy #SGT212 #FALCONTrial #RareDiseaseAdvocacy #PatientAdvocate #RareDiseaseResearch #BiotechInnovation #MitochondrialDisease #Ataxia#PrecisionMedicine #ClinicalTrials #HopeInScience #CureFA #FARA#NeurodegenerativeDisease #MedicalBreakthrough #ParentAdvocate#ProgressPotentialPossibilitiesSupport the show

Send a textDonna Letier is the Co-Founder and CEO of Gardenuity ( https://gardenuity.com/ ), a gardening and well-being company dedicated to helping people grow healthier lifestyles through accessible, personalized gardening experiences.An entrepreneur with a background spanning consumer brands, hospitality, and lifestyle innovation, Donna launched Gardenuity to bridge the gap between everyday wellness and nature — making gardening approachable even for people without outdoor space, time, or prior experience.Under her leadership, Gardenuity has pioneered customized container and desktop gardening systems designed to support mental health, stress reduction, nutrition, and meaningful daily rituals. Her work sits at the intersection of preventive health, behavioral wellness, and environmental connection, with growing recognition of gardening's role in cognitive health, emotional regulation, and caregiver resilience.Donna is also an advocate for using gardening as a tool for intergenerational connection and memory engagement, exploring how sensory interaction with plants — from scent and touch to nurturing routines — can support individuals living with memory loss while providing caregivers with moments of restoration and purpose.#Alzheimers #BrainHealth #CognitiveHealth #DementiaCare #CaregiverSupport #HealthyAging #Longevity #Neuroplasticity #MentalWellness #PreventiveHealth #Gardening #HorticulturalTherapy #MemoryCare #AgingWell #LifestyleMedicine #Wellness #BrainLongevity #Caregiving #NatureHeals #ProgressPotentialPossibilitiesSupport the show

Send a textDr. Karsten Eastman, Ph.D. is the CEO and Co-Founder of Sethera Therapeutics ( https://setheratx.com/ ), a company focused revolutionizing peptide-based drug development with a cutting-edge enzymatic cross-linking technology, and their platform enables the synthesis of highly stable, polymacrocyclic peptides designed to engage multiple targets simultaneously, offering unparalleled precision in therapeutic design.Trained as a chemist at the University of Utah, where he earned his PhD in 2023, Dr. Eastman has built his career at the intersection of peptide synthesis, protein engineering, and radical enzymology. His work focuses on understanding how enzymes choreograph complex molecular transformations — and then harnessing those principles to build programmable, drug-like molecules.In collaboration with researchers at the University of Utah, Dr. Eastman and his team recently published in Proceedings of the National Academy of Sciences a breakthrough discovery involving PapB, a radical S-adenosyl-L-methionine (SAM) enzyme capable of installing precise, durable thioether “staples” into peptides in a single enzymatic step. This work opens vast new chemical space for macrocyclic peptide therapeutics and offers a powerful new approach to targeting diseases long considered “undruggable.”At Sethera Therapeutics, Dr. Eastman is translating this enzymatic platform into next-generation peptide medicines that aim to combine the selectivity of biologics with the drug-like properties of small molecules.#PeptideTherapeutics #DrugDiscovery #Biotechnology #Enzymology#RadicalSAM #PapB #SetheraTherapeutics #UndruggableDiseases#MacrocyclicPeptides #Bioengineering #Therapeutics #Innovation #ScienceBreakthrough #PeptideDrugs #EnzymeTechnologySupport the show

Send a textSusie Singer Carter ( https://en.wikipedia.org/wiki/Susie_Singer_Carter ) is an award-winning filmmaker ( https://www.gogirlmedia.com/ ) and caregiver advocate with a powerful new docuseries, No Country For Old People ( https://www.amazon.com/gp/video/detail/B0F7D1RR5X/ref=atv_dp_share_cu_r  ), a Gold Anthem Award-winning exposé on nursing home neglect and the systemic failures facing America's elderly. Through film, podcasting, and activism, she has become one of the most compelling creative voices in Alzheimer's awareness and elder care reform.Susie first captured international attention with her Oscar-qualified short film My Mom and The Girl, starring Valerie Harper in her final performance — a deeply personal story born from Susie's own caregiving journey. From writing and producing Bratz the Movie, to co-producing Soul Surfer, Susie has navigated Hollywood at every level — but it's her advocacy-driven work that has become her defining voice.Susie is also the creator and host of the award-winning podcast Love Conquers Alz ( https://podcasts.apple.com/us/podcast/love-conquers-alz/id1492023291 ), and she serves as host of the 3rd & Fairfax for the Writers Guild of America West.Most recently, Susie wrote, directed, and produced the 3-part docuseries No Country For Old People ( https://www.youtube.com/watch?v=Loa4tGZ3GwI ), recipient of the 2024 Gold Anthem Award for Health Awareness. The film is a searing examination of nursing home neglect, systemic healthcare failures, and the human cost of institutional indifference — a subject she knows not just as a filmmaker, but as a daughter who lost her mother to Alzheimer's.Susie also leads Respect Oversight Advocacy Reform for Long Term Care ( https://www.roar4ltc.org/ ) a 501c3 nonprofit movement that is embracing the power of storytelling to engage and mobilize the public, with a strong focus on younger generations, to demand dignity,  accountability, and reform in long-term care.Susie Singer Carter doesn't just tell stories. She uses them to fight for change.Important Episode LinksNo Country For Old People; a Nursing Home Exposé -https://www.amazon.com/gp/video/detail/B0F7D1RR5X/ref=atv_dp_share_cu_r http://nocountryforoldpeople.com/ https://www.youtube.com/@UCZGC8Htb549M2TNVSR67FOw My Mom and the Girl - https://vimeo.com/266772460 Respect Oversight Advocacy Reform for Long Term Care - https://www.roar4ltc.org/#SusieSingerCarter #NoCountryForOldPeople #ElderCare #NursingHomeCrisis #CaregiverAdvocacy #AlzheimersAwareness#HealthcareReform #DementiaCare #PublicHealth #AgingPopulation#LongTermCare #HealthPolicy #CaregiverLife #ElderJustice #LongevitySupport the show

Send a textWhy do some scientific breakthroughs begin with ridicule?In this episode, we explore cancer research, serendipity, and the philosophy behind unconventional biomedical innovation.Dr. Alexander Shneider, Ph.D. is a biotech entrepreneur and scientist with more than three decades of experience spanning oncology, immunology, vaccines, and translational medicine. He is the Founder and CEO of CureLab Oncology ( https://www.curelaboncology.com/ ), where he is leading the development of a novel biological agent designed to fight cancer through a dual approach—stimulating anti-tumor immunity while also addressing the chronic inflammation that often underlies disease progression.CureLab's lead therapeutic, Elenagen, has demonstrated a strong safety profile and encouraging signals of clinical benefit in international Phase II studies, and is being explored both as an adjunct to standard cancer treatments and for its broader potential in inflammation-driven and age-associated diseases. The platform's reach may extend beyond human medicine, with ongoing interest in applications for oncology in companion animals.Over the course of his career, Dr. Shneider has advised biotechnology, pharmaceutical, and investment organizations across areas including R&D strategy, licensing, technology transfer, product development, and intellectual property. He previously founded CureLab, Inc., where he worked on tools for the rational design of DNA vaccines and the development of broad-spectrum influenza vaccine concepts.In academia, Dr. Shneider has held professor-level appointments and led the Genetic Vaccine Laboratory at Sechenov University, where he helped establish multicenter clinical research infrastructure focused on diseases involving chronic inflammation. His research has also explored evolutionarily conserved RNA structures as targets for antiviral therapies and next-generation vaccine design.In addition to his scientific and entrepreneurial work, he serves on the editorial boards of several peer-reviewed journals in immunology and aging research, reflecting his long-standing engagement at the intersection of basic science, clinical translation, and biotechnology innovation.#CancerResearch #BiomedicalScience #CancerInnovation#ScientificDiscovery #PhilosophyOfScience #Biotech #MedicalInnovation#Oncology #BreakthroughScience #StartupScience #SciencePodcast #DrugDevelopment #Serendipity #Innovation  #FutureOfMedicineSupport the show

Send a textDr. Raza Bokhari, MD ( https://www.razabokhari.com/ ) is the Executive Chairman and Chief Executive Officer of Medicus Pharma Ltd. ( https://medicuspharma.com/ ), a precision-guided biotechnology company focused on accelerating the clinical development of novel and potentially disruptive therapeutic assets designed to transform the standard of care.A physician turned serial entrepreneur, Dr. Bokhari has built a distinguished career identifying, aggregating, and advancing life sciences, healthcare services, and pharmaceutical R&D companies. He is also the Managing Partner of RBx Capital, LP, an investment fund dedicated to biotech and life sciences innovation.Previously, Dr. Bokhari served as Executive Chairman and CEO of FSD Pharma, where he led a strategic transformation of the company from medicinal cannabis into a clinical-stage pharmaceutical R&D organization. Under his leadership, the company achieved a NASDAQ listing in January 2020 and raised nearly $100 million in institutional capital to support growth and expansion.Dr. Bokhari earned his Doctor of Medicine degree from Rawalpindi Medical College at the University of Punjab and holds an Executive MBA from Temple University's Fox School of Business.Beyond his corporate leadership, Dr. Bokhari is Vice Chairman of the World Affairs Council of Philadelphia. He previously served on the Board of Temple University's Fox School of Business as Chairman of the Executive Advisory Committee, and as a Trustee of both The Franklin Institute and the Foreign Policy Research Institute.Through his family foundation, Dr. Bokhari is deeply committed to philanthropy and community engagement. In recognition of a $1 million gift to Temple University, the Fox School named its Innovation & Entrepreneurship Institute Suite in his honor. In 2018, he was named a Centennial Honoree by the Fox School — recognized among a select group of entrepreneurs, visionaries, and disruptors who have shaped the institution and the broader business world since 1918.#Biotech  #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #MedicusPharma #Phase2Biotech #BiotechStrategy #DeRiskThenPartner #CapitalEfficient #Investing #PharmaInvesting #PrecisionBiotech #OncologyInnovation #DrugRepurposing #MedicalInnovation #HealthcareStrategy #ClinicalDevelopment #BiotechBusinessModelSupport the show

Send a textAntimicrobial resistance is a systems failure — not just a prescribing problem.  Olivier Niyonshima, Founder of ZeroX Intelligence and Medikal Africa, explains how NVIDIA-backed edge AI infrastructure is transforming healthcare across Africa.Olivier Niyonshima ( https://olivierniyonshima.com/ ) is the Founder and CEO of ZeroX Intelligence ( https://zeroxintelligence.com/ ), a Rwandan–Canadian AI company focused on building practical, production-grade technology for healthcare, agriculture, and education across Africa.He leads Medikal Africa ( https://www.medikalafrica.com/ ), an AI-powered clinical intelligence platform designed to combat antimicrobial resistance and strengthen digital health systems in real-world African healthcare environments. Rather than treating AMR as an awareness problem, Olivier approaches it as a systems failure—one driven by delayed diagnostics, fragmented data, and weak decision support—and is building infrastructure to fix that.Olivier's work has been recognized globally. Medikal Africa is an NVIDIA Inception Startup, selected after technical and product review for its work in GPU-accelerated, edge-first healthcare AI. He also serves as a Youth Digital Health Champion with the Africa Centres for Disease Control and Prevention, contributing to continental digital health strategy, policy dialogue, and systems strengthening.Through ZeroX Intelligence, Olivier is also leading on-the-ground healthcare infrastructure initiatives, including the deployment of autonomous UV-C disinfection robotics to improve infection prevention in clinical settings. His work is grounded in a clear mission: ensuring Africa doesn't just host pilots or consume technology, but leads in building scalable systems that work in real conditions.#OlivierNiyonshima #ZeroXIntelligence #MedikalAfrica#AntimicrobialResistance #AMR #HealthAI #DigitalHealth #AfricaInnovation #NVIDIAInception #EdgeAI #ClinicalAI #HealthcareTechnology #AIinHealthcare #PublicHealth #SuperbugsSupport the show

Send a textNishant Rastogi is the inaugural Managing Director of Lupus Ventures ( https://www.lupusventures.org/ ), the venture investment fund of the Lupus Research Alliance ( LRA - https://www.lupusresearch.org/ ), where he serves on the Investment Committee. In this role, he leads all aspects of the fund — from sourcing and evaluating opportunities to structuring deals and managing the portfolio — while overseeing team recruitment, business development, and coordination with the fund's Investment Committee and Scientific Advisory Board.Lupus Ventures is the world's only venture fund dedicated to systemic lupus erythematosus (SLE) and related autoimmune conditions. It aims to accelerate the development of new therapies and diagnostics that improve care and deliver meaningful impact for the millions of people living with lupus worldwide.A seasoned life sciences investor with over a decade of experience in venture capital and private equity, Mr. Rastogi has served as a Board Director and operating partner for multiple biotech and medtech companies. Prior to Lupus Ventures, he was Vice President and Head of Transactions at New Rhein Healthcare Investors, where he helped establish the firm's U.S. office, executed transactions across diverse therapeutic areas, and managed a portfolio totaling over $200 million in direct investments. His work spanned financing, clinical development, regulatory strategy, manufacturing, and commercialization. Notable investments include Corsair, Theranica, Alveus, American Injectables, Butterfly Medical, Softhale, EirCor, and Neuraptive.Earlier in his career, Mr. Rastogi was a founding associate at Broadview Ventures, a Boston-based venture capital fund focused on cardiovascular innovation, and has advised multiple disease research foundations — including Beyond Celiac and Parent Project Muscular Dystrophy — on venture fund formation and the intersection of philanthropy and private investment in advancing medicines and health equity. He began his career as an analyst at Fidelity Investments.Mr. Rastogi holds a B.A. in Economics and Mathematical Finance from Dartmouth College, an MBA from Northwestern University (Kellogg), a Medical Science Certificate from Harvard, and a Certificate in Climate Change and Health from Yale.#Lupus #AutoimmuneDisease #LupusResearch #BiotechInnovation #Immunology #HealthcareInnovation #PrecisionMedicine #WomensHealth #HealthEquity #VentureCapital #Biotechnology #SystemicLupus #LupusAwareness #MedicalBreakthrough #LifeSciencesSupport the show

Send a textOver the past few years, artificial intelligence has rapidly entered drug discovery — but one of the true “holy grail” challenges inside pharma is no longer just predicting what proteins look like, but understanding how molecules actually interact: how proteins bind drugs, antibodies, RNA, and each other, and how those insights can guide better decisions long before anything reaches the lab.Early breakthroughs in structure prediction made protein models widely accessible, but real biology happens at interfaces, in motion, and often in fleeting conformations that determine whether a therapy ultimately succeeds or fails. Today's conversation explores what it means to move into this next chapter — where structural predictions are translated into actionable insight for real-world drug development.Joining us are two scientists from Merck KGaA, Darmstadt, Germany ( https://www.emdgroup.com/en ), working at the intersection of protein structure prediction, molecular dynamics, and generative design, helping to build internal platforms that turn computational models into practical decision tools for therapeutic discovery.Dr. Stephanie Linker, Ph.D. is a Senior Computational Biochemist in Merck's Group Digital Innovation unit, where she leads initiatives in generative antibody design, de novo protein binder development, and advanced structure prediction platforms. Her work focuses on how molecular shape, flexibility, and dynamics influence whether a designed molecule actually performs in biological systems.Dr. Philipp Schnee, Ph.D. is a Computational Protein Design expert at Merck KGaA, currently part of the GoGlobal Data & AI rotation program. His research bridges high-resolution molecular dynamics simulations with experimental biochemistry to understand protein function, mutation effects, and mechanisms that can be leveraged for enzyme engineering and inhibitor design.Together, their work reflects a broader shift happening across the pharmaceutical industry — away from static structures and standalone models, and toward integrated platforms that combine folding, binding, ranking, and experimental validation to guide smarter, faster therapeutic decisions.In this episode, we explore what these next-generation tools can do today, where their limitations remain, and why the ability to move from structure prediction to decision-ready insight may become one of the most important frontiers in modern drug discovery.AI drug discovery, protein structure prediction, computational biology, biologics design, pharmaceutical R&D#DrugDiscovery #ArtificialIntelligence #AlphaFold #ProteinFolding#Biotech #PharmaInnovation #ComputationalBiology #StructuralBiology #AIinHealthcare #AntibodyEngineering #MolecularDynamics #FutureOfMedicine #SystemsBiology #LifeSciences #ProgressPotentialPossibilities #MachineLearning #BioTechPodcastSupport the show

Send a textJoin us for a deep dive with Dr. Sonia Grego, scientist, engineer, and entrepreneur at the forefront of redefining human health through everyday biological data.In this episode, we explore how Dr. Grego's groundbreaking work with Coprata's smart toilet platform is turning stool into actionable health insights — passively, seamlessly, and in the comfort of your own home. We discuss biomarkers, gut health monitoring, and how cutting-edge sensor and AI technologies are making preventive medicine more personalized and accessible.Dr. Grego is Co-Founder & CEO of Coprata and Director of the Duke Smart Toilet Lab, where she studies biochemical signals in everyday human waste to unlock early, equitable, and personalized health insights. With a PhD in Physics from the University of Copenhagen, dozens of peer-reviewed publications, and multiple U.S. patents, she bridges rigorous science, sensor technology, and real-world health impact.This episode is a must-watch for anyone interested in digital health, preventive medicine, gut health, sensors, and the future of biomedical technology.Learn more about Coprata: https://www.coprata.comLearn more about the Duke Smart Toilet Lab: https://smarttoilet.pratt.duke.edu/peopleLearn more about the Nestlé Health Science FIBER-IMPACT study:  https://www.nestlehealthscience.us/stories/nestle-health-science-launches-landmark-study-uncover-impact-lifestyle-gut-healthFollow the show for more deep dives into health innovation and emerging biotech.#SmartToilet #Coprata #GutHealth #DigitalHealth #PreventiveMedicine #Biomarkers #HealthTech #StoolAnalysis #MedicalInnovation #FutureOfHealthcare  #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #PodcastSupport the show

Send a textMeduza documentary interview with director Roc Morin.A Ukrainian actor who once played a sniper on screen is recruited as one in real life—this conversation explores how war reshapes identity, memory, and meaning.Roc Morin is a filmmaker and journalist whose work explores the intersection of conflict, culture, and the inner lives of people living through historical rupture.He is the director of the documentary MEDUZA, which follows Ukrainian artist and actor Pavlo Aldoshyn, who became a sniper when the full-scale invasion began in 2022—drawing, uncannily, on skills he had previously learned playing a sniper in a film role. Shot over two years, MEDUZA traces Pavlo's psychological and spiritual transformation as war reshapes not only his life, but the framework he uses to understand himself and the world.Before turning to documentary filmmaking, Roc reported extensively on Ukraine beginning in 2014. Following the full-scale invasion in 2022, he entered the country in the earliest days of the war, crossing the border on foot and making his way to Lviv when no formal transportation was available.Roc previously directed the documentary You Are My Audience and served as a producer on Werner Herzog's Family Romance, LLC. MEDUZA was produced with his longtime collaborator Leïla Wolf, whose creative partnership deeply shaped the film.Filmed across Ukraine, the United States, Japan, India, and Ecuador, MEDUZA reflects Roc's distinctive approach to documentary filmmaking—one that resists spectacle in favor of intimacy, and asks not only what is happening in the world, but how people metabolize it internally.This episode features MEDUZA director Roc Morin discussing the story behind the documentary.Important Episode Links:https://www.rocmorin.com/Trailer: https://www.youtube.com/watch?v=XwcjBl2RayoIMDb: https://www.imdb.com/name/nm9128669/#Meduza #UkraineWar #DocumentaryFilm #WarAndIdentity #Transformation #ImmortalJellyfish #HumanCondition #WarStories#Filmmaking #IndependentFilm #PsychologyOfWar#ArtAndWar #DocumentaryInterview #ProgressPotentialAndPossibilities #IraPastor #PodcastSupport the show

Send us a textBrandon Ganske is Chief Marketing Officer (CMO) of LifeRx.md ( https://liferx.md/ ), a U.S.-based telehealth and wellness company providing clinically supervised programs for metabolic, hormonal, cellular, and performance health. Through its secure, customer-centric digital platform, LifeRx.md connects patients with licensed U.S. medical providers, streamlines treatment access, and delivers provider-reviewed therapies in a secure and private environment.LifeRx.md empowers individuals to take control of their health with confidence, clarity, and support. Brandon comes to healthcare from the front lines of e-commerce and direct-to-consumer brand building, with more than a decade of experience scaling high-growth digital businesses. Before entering telehealth, he founded and operated multiple e-commerce ventures, overseeing everything from product development and sourcing to performance marketing and customer acquisition.Brandon is also the founder of Influenceish ( https://www.influenceish.com/ ), a marketing and growth consultancy focused on helping brands build authentic customer relationships in increasingly crowded digital marketplaces.Today, at LifeRx.md, Brandon sits at the intersection of healthcare, technology, and consumer behavior—working on how telehealth platforms earn trust, communicate clinical value, and adapt to rapidly changing expectations around weight loss, hormones, and performance-driven medicine.#FutureOfHealthcare #Telehealth #PrimaryCare #DigitalHealth #HealthInnovation #TrustInMedicine #ClinicalCare #MedicalEthics#ResponsibleInnovation #EvidenceBasedMedicine #HumanOptimization#PreventiveHealth #PerformanceHealth #Longevity #MetabolicHealth#HealthcareTransformation #CareDelivery #HealthSystems #BrandonGanske #PatientCentricCare #ValueBasedCare #HealthPodcast #SciencePodcast #MedTech #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show

Send us a textMohammed “Mo” Abouelsoud is a neuroscientist-entrepreneur whose career sits at the intersection of brain science, noninvasive neuromodulation, and precision healthcare. He is the CEO of U: The Mind Company ( https://uthemind.company ), where he leads the development of precision, noninvasive neuromodulation technologies aimed at restoring dysfunctional brain networks in Parkinson's disease and other neurological disorders. Mo's journey into neuroscience began long before the boardroom—rooted instead in hands-on clinical exposure and early immersion in brain imaging and data science. While training at The Ohio State University Wexner Medical Center, he worked in a neuromodulation data analysis lab, learning to map structural and functional brain connectivity using DTI and fMRI, and gaining fluency in tools such as MATLAB and FSL. This early exposure shaped his enduring interest in the brain not as isolated regions, but as dynamic, networked systems that can be measured, modeled, and—critically—modulated.At OSU, Mo further expanded his technical foundation through research spanning nanotechnology, fluorescence imaging, and signal measurement, synthesizing DNA-gold nanoparticle conjugates for precision sensing. Across these experiences, a unifying question emerged: how can we quantify brain function objectively, and how can we intervene noninvasively to restore lost connectivity?That question became the backbone of his entrepreneurial work. Prior to founding U: The Mind Company, Mo co-founded Tremo, a quantitative tracking platform designed to objectively measure motor symptoms and treatment response in neurological disease—an early step toward personalized, data-driven neurology.At U: The Mind Company, Mo now leads a multidisciplinary effort combining transcranial electrical stimulation (tES), neuroimaging, advanced signal analytics, and AI-driven interpretation within the company's Compressive Healthcare Intelligence Platform (CHIP). His work has helped demonstrate that targeted frontal lobe stimulation can significantly enhance functional connectivity in Alzheimer's disease networks, with observed increases in local and interhemispheric coherence that suggest meaningful neuroplastic re-engagement of impaired circuits. In Parkinson's disease, his team has shown measurable reductions in tremor and dyskinesia using objective video analysis and motor tracking—bringing rigor and quantification to outcomes that have traditionally been subjective.Threaded throughout Mo's neuroscience journey is an unusually holistic worldview. Before entering research and medicine, he spent years working in permaculture and regenerative farming, an experience that deeply influenced his systems-level thinking. Just as ecosystems thrive through balance, feedback, and interdependence, Mo approaches the brain as a living network—one that can be guided back toward health through precise, adaptive intervention rather than blunt force. Today, Mo Abouelsoud is driven by a singular mission: to translate neuroscience into scalable, noninvasive technologies that restore brain function, dignity, and agency to patients, while redefining how neurological disease is measured, treated, and understood.Important Episode Link - Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms -https://clinicaltrials.gov/study/NCT07182058 #MohammedAbouelsoud #UTheMindCompany #Noninvasive #Neurotechnology #Neuromodulation #Electroceuticals #TranscranialElectricalStimulation #TranscranialDirectCurrentStimulation #TranscranialAlternatingCurrentStimulation #AlzheimersDisease #ParkinsonsDisease #PsychiatricDisorders #DigitalTwinBrain #STEM #Innovation #Science #Technology #ReSupport the show

Send us a textDr. Christopher Buck, Ph.D. ( https://cbuck.substack.com/ ) is Senior Investigator, Laboratory of Cellular Oncology, And Head, Tumor Virus Molecular Biology Section, Center for Cancer Research, at the U.S. National Cancer Institute ( https://ccr.cancer.gov/staff-directory/christopher-b-buck ).Dr. Buck's lab focuses on the virion proteins of a family of viruses called polyomaviruses, and their research ranges from basic investigation of the mechanisms through which polyomaviruses infect cells to translational development of virus-like particle vaccines. They also maintain an active interest in discovering new virus species, with the goals of uncovering human disease associations and understanding the evolutionary history of cancer-causing viruses.Dr. Buck received a bachelor's degree in Molecular Cellular and Developmental Biology from the University of Colorado at Boulder and a Ph.D. from the Johns Hopkins School of Medicine.  Dr. Buck's graduate research in Dr. Robert Siliciano's lab focused on the translation and immunogenicity of the HIV-1 capsid protein Gag. For his graduate work, Dr. Buck received the Alicia Showalter Reynolds Award. In 2001, Dr. Buck began post-doctoral training in the Lab of Cellular Oncology, where he developed systems for producing human papillomavirus (HPV)-based gene transfer vectors (pseudoviruses). His work using HPV vectors ranged from basic studies of HPV virion structure and morphogenesis to translational research identifying candidate topical microbicides for blocking HPV transmission. For his work in these areas, Dr. Buck, and his mentors, Drs. John Schiller and Doug Lowy, shared the 2006 Norman P. Salzman Award. In 2007, Dr. Buck joined the faculty of the NCI's Center for Cancer Research as an Investigator. In 2013, he shared a second Salzman Award in recognition of his mentoring of Dr. Rachel Schowalter.  Dr. Buck was awarded tenure in 2014.#ChristopherBuck #CellularOncology #TumorVirus #MolecularBiology #NationalCancerInstitute #Pseudovirus #Papillomavirus #Capsid #Polyomaviruses #OralVaccines #YeastProducedAntigens #MucosalImmunology #FermentedBeverages #BeerBasedVaccines #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show